US FDA approval based on 98 percent response rate in multiple myeloma patients treated once with Carvykti (ciltacabtagene autoleucel, cilta-cel).
List view / Grid view
Icahn School of Medicine at Mount Sinai
The investigational antibody evinacumab was able to lower triglycerides by up to 82 percent in severe hypertriglyceridemia patients with acute pancreatitis.
New research shows a second COVID-19 vaccine dose may be unnecessary in individuals previously infected with SARS-CoV-2 and needlessly exposes individuals to higher rates of adverse effects.
The chimeric hemagglutinin (HA)-based vaccine induced a strong, functional immune response that lasted at least 18 months.
Eli Lilly presents new data for their mirikizimab treatment for Crohn’s disease.
Mount Sinai shows the potential link between Parkinson's disease and inflammatory bowel disease, suggests anti-TNFα therapy may reduce the risk of developing Parkinson's...